Imaging Biometrics

Elm Grove, WI, USA  All United States companies → Founded 2007
Imaging AI Specialist Specialty-Focused AI
Neurosurgery Oncology Radiology
Neurology AI Oncology AI Radiology & Imaging AI
Acquired/Corporate Backed (subsidiary of IQ-AI Ltd) — $24.1K (over 9 rounds, including grants)

Products

IB NEURO
Imaging Biometrics
Neurology AI
IB Neuro by Imaging Biometrics is an FDA-cleared AI-powered MRI and CT perfusion platform that generates quantitative relative cerebral blood volume (rCBV) maps, providing critical insights for brain tumor diagnosis, grading, and treatment monitoring.

See all 1 product →

About Imaging Biometrics

Imaging Biometrics (IB) is a healthcare AI company dedicated to integrating advanced imaging analysis into clinical practice, offering sophisticated yet intuitive software solutions for clinicians and researchers. The company’s core offerings include a suite of AI-powered post-processing software applications designed to enhance and standardize medical image interpretation, particularly in neuro-oncology. These tools, such as IB Neuro™, IB Diffusion™, IB Delta Suite™, and IB DCE™, provide crucial physiological information like true regions of contrast enhancement, tumor blood volume, and flow, aiding in the diagnosis, grading, and monitoring of brain tumors.

Beyond brain tumor assessment, IB’s portfolio extends to other areas like kidney stone analysis with StoneChecker™ and innovative “gad-free” imaging technology, IB Zero G, which uses AI to synthesize contrast-enhanced images from non-contrast inputs, potentially reducing the need for gadolinium-based contrast agents. By delivering quantitative and automated analyses, Imaging Biometrics aims to improve diagnostic precision, streamline clinical workflows, and ultimately support more informed treatment decisions for patients. The company also has a therapeutic focus, sponsoring clinical trials for oral gallium maltolate in glioblastoma treatment.

What Physicians Need to Know

Neuro-Oncology Specialization
Imaging Biometrics (IB) is highly specialized in neuro-oncology, offering a suite of AI-powered applications like IB Neurou2122, IB Delta T1 Maps, and Fractional Tumor Burden (FTB) maps for diagnosing, grading, and monitoring brain tumors.
Quantitative Imaging Analysis
The company focuses on delivering truly quantitative and standardized data from medical images (MRI, CT), enabling precise measurement and comparison of treatment effects over time.
Advanced Perfusion & Diffusion Imaging
IB provides sophisticated tools for analyzing MR perfusion (Dynamic Susceptibility Contrast (DSC), Arterial Spin Labeling (ASL), Dynamic Contrast-Enhanced (DCE)) and Diffusion-Weighted Imaging (DWI) to gain critical insights into tissue structure and pathology.
Non-Contrast Imaging Solutions
A key differentiator is their development of 'gad-free' imaging, which uses AI to synthetically generate post-contrast images, and IB ASL, which utilizes the body's own blood as a natural tracer, reducing the need for gadolinium-based contrast agents.
Automated Workflow & Efficiency
Products like IB Rad Techu2122 automate complex imaging tasks and streamline post-processing, significantly reducing manual steps and accelerating the generation of advanced image maps by over 85%.
Mobile Collaboration & Accessibility
IB Nimbleu2122 is a mobile application that facilitates secure, real-time collaboration among multi-disciplinary medical experts, enhancing communication and treatment decisions. Their solutions also aim to bring high-end imaging capabilities to community hospitals.
Physician Tip

For physicians, Imaging Biometrics' tools offer enhanced diagnostic precision by providing critical, quantitative insights into tumor biology, vasculature, and tissue pathology, aiding in differentiating tumor types and assessing treatment response more accurately. The ability to perform 'gad-free' imaging with AI and ASL is particularly beneficial for patients where contrast agents are contraindicated. The automated workflows and seamless integration into existing systems significantly improve efficiency, reducing administrative burden and allowing more focus on patient care. Furthermore, the mobile collaboration features enable faster, more informed decision-making across multidisciplinary teams, ultimately leading to greater confidence in treatment strategies and improved patient outcomes.

Imaging Biometrics' solutions are designed as platform-independent software plug-ins that seamlessly integrate into existing medical image visualization applications, imaging systems, PACS, or medical viewers. They have established distribution agreements with major healthcare technology providers like GE HealthCare and Blackford Analysis, and are compatible with FDA-cleared platforms such as the aycan workstation, ensuring broad accessibility and streamlined deployment within diverse clinical environments.

Products by Imaging Biometrics

1 product in the directory

IB NEURO
Imaging Biometrics
Neurology AI
IB Neuro by Imaging Biometrics is an FDA-cleared AI-powered MRI and CT perfusion platform that generates quantitative relative cerebral blood volume (rCBV) maps, providing critical insights for brain tumor diagnosis, grading, and treatment monitoring.

Reviews & Opinions

No web reviews on file yet for Imaging Biometrics. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Imaging Biometrics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Imaging Biometrics →

View all on YouTube

Press & Coverage

London Stock Exchange
Imaging Biometrics Expands Global Distribution Agreement with GE HealthCare to Include FTB Express Maps and QSMetricu2122
Imaging Biometrics has expanded its distribution agreement with GE HealthCare to include FTB Express maps and QSMetric software, enhancing access to advanced neuroimaging solutions for brain tumor diagnosis and monitoring. This builds upon their existing agreement for IB Neuro and Delta T1 maps.
2025-12
Investing.com
Imaging Biometrics reports phase II trial results for brain tumor software
Imaging Biometrics announced positive results from the EAF151 Phase II clinical trial, demonstrating that its IB Neuro software can provide early, objective signals of treatment response for recurrent glioblastoma patients. The technology aims to offer response signals within weeks, potentially aiding in earlier determination of treatment effectiveness.
2026-05
RNS News | IBAI - IMAGING BIOMETRICS LIMITED
Imaging Biometrics Enters Agreement with MedImageMetric to Commercialize QSM Technology
Imaging Biometrics, LLC has partnered with MedImageMetric, LLC to commercialize its patented QSMetricu2122 software, an FDA-cleared quantitative susceptibility mapping (QSM) MRI technology. This collaboration aims to enhance diagnostic capabilities for various diseases by measuring tissue response to magnetic fields.
2025-09
Applied Radiology
AJR Review Endorses Advanced Imaging Techniques, Validating Imaging Biometrics' Tools for Brain Tumor Assessment
Imaging Biometrics welcomed an expert consensus in the American Journal of Roentgenology (AJR) endorsing advanced imaging techniques, specifically dynamic susceptibility contrast MRI (DSC-MRI), for evaluating high-grade gliomas. This validates IB's technology, including IB Neuro and Fractional Tumor Burden (FTB) maps, which distinguish tumor progression from treatment effects.
2025-07
Investing.com
Imaging Biometrics releases next-gen medical imaging platform
Imaging Biometrics, LLC announced the release of a new version of IB Clinic, its comprehensive medical image processing suite. This updated platform integrates multiple imaging technologies into a single automated solution, designed to reduce manual intervention in medical image processing workflows.
2025-11
Simply Wall St
Imaging Biometrics Limited Publishes Phase 1 Clinical Trial Results Of Oral Gallium Maltolate In Recurrent Glioblastoma And Reopens Expanded Access Programme
Imaging Biometrics Limited announced the publication of Phase 1 clinical trial results for oral gallium maltolate (GaM) in recurrent glioblastoma in the peer-reviewed journal Neuro-Oncology Advances. The company also reopened its Expanded Access Programme for GaM.
2026-06
AllMind AI News
Imaging Biometrics draws line under cancer drug plans to focus on imaging growth
Imaging Biometrics has decided to discontinue plans for a Phase II trial of gallium maltolate, shifting its focus and resources to its revenue-generating imaging software business. This strategic pivot aims to prioritize commercial growth and financial stability.
2026-06
Kalkine Media
Imaging Biometrics Limited (IBAI) Finalizes Share Sub-Division, Issuing 246,709,789 Shares at u00a30.005 Each
Imaging Biometrics Limited has officially completed its share sub-division, resulting in 246,709,789 ordinary shares with a nominal value of u00a30.005 each. This capital restructuring was formally approved by the Jersey Financial Services Commission.
2026-07

Frequently Asked Questions

Imaging Biometrics provides several AI-powered software solutions primarily for neuroimaging, including IB Neuro for quantitative MR DSC perfusion, IB Delta Suite for T1 mapping, FTB Express maps for automated tumor visualization, and QSMetric for quantitative susceptibility mapping. They also offer IB Diffusion for MR diffusion-weighted image analysis and StoneChecker for kidney stone assessment.
Yes, Imaging Biometrics' products, such as the IB Clinic suite (comprising IB Neuro, IB Diffusion, and IB Delta Suite), have received U.S. FDA 510(k) clearance. The company also holds CE marking for products like IB Neuro and generally states it has achieved regulatory approvals in both the US and Europe.
Specific pricing models for Imaging Biometrics' AI software are not publicly detailed in the search results. Healthcare organizations typically prefer predictable and transparent pricing, often involving hybrid models with subscription and usage-based components. For detailed pricing and to obtain a quote, it is recommended to contact Imaging Biometrics directly through their website or sales team.
Imaging Biometrics emphasizes comprehensive customer support throughout the user journey, including installation, training, and ongoing maintenance. Their support team is readily available to address any issues, aiming to minimize disruptions to clinical workflows.
Yes, Imaging Biometrics has significant partnerships, notably an expanded global distribution agreement with GE HealthCare for several neuroimaging solutions like IB Neuro, Delta T1 maps, FTB Express, and QSMetric. They also distribute their products through Arterys's medical AI platform and offer solutions as plug-ins for aycan workstations.
Imaging Biometrics is a subsidiary of IQ-AI Limited, a publicly traded micro-cap company. While it has a long history since its founding in 2007, recent reports indicate limited revenue and dependence on external funding, with a recent strategic shift to reallocate resources from drug development to accelerate growth in its core imaging solutions business to strengthen its financial foundation.
Imaging Biometrics states its commitment to internet privacy and outlines a privacy policy regarding personal data collection and use, noting they do not intentionally collect sensitive personal information. While specific technical security details for their AI products aren't extensively detailed in public searches, general regulatory compliance for medical imaging software often includes robust data integrity, access controls, and audit trails.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.